Aquestive Therapeutics’ (AQST) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report released on Wednesday morning, Benzinga reports. They currently have a $9.00 target price on the stock.

Several other analysts have also recently commented on AQST. HC Wainwright reiterated a buy rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, June 5th. Piper Sandler started coverage on shares of Aquestive Therapeutics in a report on Thursday, April 11th. They issued an overweight rating and a $10.00 target price on the stock. Raymond James started coverage on shares of Aquestive Therapeutics in a report on Thursday, March 28th. They issued an outperform rating and a $7.00 target price on the stock. SVB Leerink started coverage on shares of Aquestive Therapeutics in a report on Friday, May 10th. They issued an outperform rating and a $8.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Aquestive Therapeutics to a strong-buy rating in a report on Friday, May 10th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $7.83.

Aquestive Therapeutics Stock Performance

AQST opened at $2.60 on Wednesday. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The firm’s fifty day moving average is $3.09 and its 200 day moving average is $3.18. The stock has a market cap of $236.70 million, a price-to-earnings ratio of -6.19 and a beta of 2.81.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The business had revenue of $12.05 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter in the prior year, the firm posted $0.11 EPS. On average, equities research analysts predict that Aquestive Therapeutics will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently added to or reduced their stakes in AQST. Armistice Capital LLC grew its holdings in Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 3,642,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after purchasing an additional 1,353,518 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth about $1,709,000. Acadian Asset Management LLC grew its stake in Aquestive Therapeutics by 238.8% in the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock worth $841,000 after acquiring an additional 388,017 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in Aquestive Therapeutics in the 1st quarter worth about $1,456,000. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.